| Primary |
| Hypercholesterolaemia |
39.0% |
| Blood Cholesterol Increased |
10.3% |
| Hypertension |
8.7% |
| Hyperlipidaemia |
8.0% |
| Diabetes Mellitus |
5.3% |
| Dyslipidaemia |
4.7% |
| Myocardial Ischaemia |
4.0% |
| Asthma |
3.7% |
| Acute Myocardial Infarction |
2.0% |
| Coronary Artery Disease |
1.7% |
| Myocardial Infarction |
1.7% |
| Blood Cholesterol |
1.3% |
| Cardiovascular Event Prophylaxis |
1.3% |
| Erectile Dysfunction |
1.3% |
| Hyperuricaemia |
1.3% |
| Osteoporosis |
1.3% |
| Prophylaxis |
1.3% |
| Benign Prostatic Hyperplasia |
1.0% |
| Blood Cholesterol Decreased |
1.0% |
| Blood Pressure |
1.0% |
|
| Myalgia |
10.7% |
| Rhabdomyolysis |
8.0% |
| White Blood Cell Count Increased |
8.0% |
| Pain In Extremity |
7.1% |
| Tendon Rupture |
7.1% |
| Vomiting |
6.3% |
| Malaise |
4.5% |
| Paraesthesia |
4.5% |
| Sensory Loss |
4.5% |
| Toxic Skin Eruption |
4.5% |
| Urticaria |
4.5% |
| Weight Decreased |
4.5% |
| Death |
3.6% |
| Nervous System Disorder |
3.6% |
| Oral Discomfort |
3.6% |
| Renal Failure Acute |
3.6% |
| Urinary Retention |
3.6% |
| Muscle Rupture |
2.7% |
| Myocardial Ischaemia |
2.7% |
| Myopathy |
2.7% |
|
| Secondary |
| Hypercholesterolaemia |
37.2% |
| Drug Use For Unknown Indication |
10.9% |
| Blood Cholesterol Increased |
9.7% |
| Product Used For Unknown Indication |
7.2% |
| Hypertension |
7.0% |
| Diabetes Mellitus |
4.3% |
| Ill-defined Disorder |
3.1% |
| Hyperlipidaemia |
2.1% |
| Acute Myocardial Infarction |
1.9% |
| Asthma |
1.9% |
| Nausea |
1.8% |
| Osteoporosis |
1.8% |
| Depression |
1.6% |
| Erectile Dysfunction |
1.6% |
| Intermittent Claudication |
1.6% |
| Irritable Bowel Syndrome |
1.6% |
| Blood Cholesterol |
1.2% |
| Prophylaxis |
1.2% |
| Prostate Cancer |
1.2% |
| Unevaluable Event |
1.2% |
|
| Sensory Loss |
14.5% |
| Rhabdomyolysis |
11.1% |
| Nervous System Disorder |
8.5% |
| Vertigo |
6.8% |
| Myalgia |
6.0% |
| Acute Respiratory Distress Syndrome |
5.1% |
| Renal Failure Acute |
5.1% |
| Urinary Tract Infection |
5.1% |
| Pain In Extremity |
4.3% |
| Vomiting |
4.3% |
| Organising Pneumonia |
3.4% |
| Pyrexia |
3.4% |
| Respiratory Rate Increased |
3.4% |
| Weight Decreased |
3.4% |
| Drug Hypersensitivity |
2.6% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
2.6% |
| Malaise |
2.6% |
| Myopathy |
2.6% |
| Polyneuropathy |
2.6% |
| Skin Ulcer |
2.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
19.6% |
| Drug Use For Unknown Indication |
16.4% |
| Hypertension |
14.9% |
| Diabetes Mellitus |
5.5% |
| Blood Cholesterol Increased |
5.4% |
| Depression |
4.4% |
| Pain |
3.3% |
| Osteoporosis |
3.0% |
| Prophylaxis |
2.9% |
| Arthritis |
2.7% |
| Hypercholesterolaemia |
2.7% |
| Rheumatoid Arthritis |
2.6% |
| Atrial Fibrillation |
2.5% |
| Gastrooesophageal Reflux Disease |
2.3% |
| Type 2 Diabetes Mellitus |
2.2% |
| Blood Cholesterol |
2.1% |
| Hyperlipidaemia |
1.9% |
| Hormone Replacement Therapy |
1.9% |
| Renal Transplant |
1.9% |
| Anxiety |
1.8% |
|
| Vomiting |
15.1% |
| Myocardial Infarction |
11.3% |
| Weight Decreased |
9.6% |
| Weight Increased |
9.1% |
| Type 2 Diabetes Mellitus |
4.4% |
| Renal Failure |
4.1% |
| Syncope |
4.1% |
| Vision Blurred |
4.1% |
| Renal Failure Acute |
3.6% |
| Somnolence |
3.6% |
| Vertebroplasty |
3.6% |
| Pain |
3.3% |
| Transient Ischaemic Attack |
3.3% |
| Drug Ineffective |
3.0% |
| Nausea |
3.0% |
| Respiratory Failure |
3.0% |
| Thrombocytopenia |
3.0% |
| Urinary Tract Infection |
3.0% |
| Ventricular Tachycardia |
3.0% |
| Breast Cancer Female |
2.7% |
|
| Interacting |
| Heart Transplant |
20.5% |
| Drug Use For Unknown Indication |
11.4% |
| Dyslipidaemia |
9.1% |
| Hypertension |
9.1% |
| Gout |
6.8% |
| Nephrotic Syndrome |
6.8% |
| Osteoarthritis |
6.8% |
| Coronary Artery Disease |
4.5% |
| Essential Hypertension |
4.5% |
| Hypercholesterolaemia |
4.5% |
| Anxiety Disorder |
2.3% |
| Atrial Fibrillation |
2.3% |
| Back Pain |
2.3% |
| Bipolar Disorder |
2.3% |
| Oedema Peripheral |
2.3% |
| Prophylaxis |
2.3% |
| Thrombosis Prophylaxis |
2.3% |
|
| Weight Decreased |
23.1% |
| Aspartate Aminotransferase Increased |
15.4% |
| Drug Interaction |
7.7% |
| Hypercreatininaemia |
7.7% |
| International Normalised Ratio Increased |
7.7% |
| Renal Failure Acute |
7.7% |
| Rhabdomyolysis |
7.7% |
| Toxic Skin Eruption |
7.7% |
| Varicose Ulceration |
7.7% |
| Vomiting |
7.7% |
|
